Alvotech ((ALVO)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Alvotech’s latest earnings call painted a cautiously optimistic picture, as management balanced clear operational progress with near-term financial strain. Executives highlighted growing biosimilar momentum, rising EBITDA margins and a strategic U.S. manufacturing partnership, yet acknowledged a sharp quarterly revenue drop, thin product margins, cash pressures and ongoing regulatory scrutiny.
Pipeline and Regulatory Progress
Alvotech underscored a busy regulatory calendar, with biologics license resubmissions for biosimilars to Simponi, Eylea, Prolia and Xgeva nearing completion. The company also filed EMA applications for AVT16 and AVT80, kept AVT29 on track for a 2026 EU filing and started enrolling patients in a pivotal trial supporting a potential U.S. submission in 2028.
Commercial Momentum and Market Share Gains
On the commercial front, AVT02 emerged as the fastest-growing Humira biosimilar in the U.S., reaching about 10% market share and reinforcing Alvotech’s competitive standing. Management noted that the company’s footprint now spans over 90 countries, with newly approved AVT03, AVT05 and AVT06 beginning to add incremental revenue streams across Europe, the U.K. and Japan.
Manufacturing Diversification Agreement
A key strategic move was a manufacturing deal with Fujifilm Biotechnologies to diversify production and add U.S.-based supply capacity. Technology transfer work is already underway, with product deliveries to the U.S. planned from the second half of 2027, aiming to support future launches while enhancing supply resilience against operational or regulatory disruptions.
Adjusted EBITDA Improvement
Despite softer top-line trends, profitability metrics showed progress, as adjusted EBITDA rose to $24 million in Q1 2026 from $21 million a year earlier. The adjusted EBITDA margin expanded to 23% from 15%, an eight-point improvement that management attributed to operating leverage and a favorable mix, signaling better earnings quality even amid production headwinds.
Gross Margin Stability
Reported gross margin held steady at a robust 57% for the quarter, edging up slightly versus the prior year period. The company indicated that this level reflects a balanced blend of product and licensing revenues, suggesting that earnings remain supported by high-margin milestone and licensing income while manufacturing throughput is temporarily constrained.
Full-Year Guidance and Longer-Term Growth Outlook
Alvotech reaffirmed its full-year 2026 revenue outlook of $650–$700 million and adjusted EBITDA guidance of $180–$220 million, implying continued double-digit growth versus 2025. Management framed 2027 as a year of strong expansion and “healthy leverage,” anchored by higher manufacturing output and materially better margins once regulatory issues are resolved and new capacity ramps.
Quarterly Revenue Decline
Beneath the upbeat long-term tone, the near-term numbers were weaker, with Q1 2026 revenues falling 20% year on year to $106 million. Executives linked the decline primarily to reduced manufacturing throughput, as the company intentionally dialed back production during facility upgrades and regulatory remediation efforts to derisk future operations.
Low Product Margin and Throughput Impact
Product economics suffered from the slowdown, with product margin slipping to just 11% in the quarter. Management acknowledged that lower throughput during 2025 and early 2026 has weighed both on product revenues and unit costs, but argued that these temporary pressures are the price of strengthening the manufacturing base ahead of a planned growth phase.
Negative Operating Cash Flow and Limited Cash Balance
Cash flow and liquidity were another pressure point, as operating cash flow came in at negative $25 million and cash on hand stood at $64 million at quarter end. The company also invested $39 million in intangibles, which management described as necessary for pipeline and regulatory progress, but which heightens near-term cash tightness until production and margin levels normalize.
High Quarterly Net Interest Payments
Financing costs remain a notable drag, with net interest payments running at roughly $35 million per quarter following a shift from PIK to cash interest in mid-2025. This sizeable recurring outflow adds another layer of strain to the balance sheet, underscoring the importance of achieving the company’s goal of stronger free cash generation as new products scale.
Regulatory Overhang and Inspection-Driven Delay
Regulatory oversight remains a key swing factor, as Alvotech is still working through prior complete response letters and an ongoing routine GMP surveillance inspection at its Reykjavik facility. The firm has deliberately slowed production to reduce operational risk and prepare for resubmissions, accepting short-term revenue disruption while signaling confidence that the inspection will conclude soon.
Revenue Mix and Lumpy Licensing Income
The quarter’s revenue mix highlighted the company’s reliance on licensing, with $55 million from licensing and $51 million from product sales. Management cautioned that such licensing and milestone income is inherently lumpy, creating volatility in reported results and complicating short-term forecasting even as it supports margins during production constraints.
Guidance and Forward-Looking Outlook
Looking ahead, Alvotech reiterated its 2026 revenue and EBITDA targets and expects the fourth quarter to be the strongest, with an ambition to turn free cash flow positive by year-end. The roadmap includes key BLA resubmissions following the current FDA inspection, 2026 submissions for Entyvio and high-dose Eylea and added U.S. supply from Fujifilm beginning in 2027, all intended to underpin a step-change in growth.
Alvotech’s earnings call ultimately reflected a company in transition, trading near-term pain for potential longer-term gain. Investors heard a mix of encouraging pipeline, margin and market share trends, offset by cash, regulatory and revenue headwinds, leaving the stock story finely balanced between execution risk and the promise of a more profitable 2027 and beyond.